福辛普利与缬沙坦对缺血性心肌病血尿酸和心功能的影响

Influence by fosinopril and valsartan on uric acid and cardiac function in ischemic cardiomyopathy

目的研究探讨福辛普利与缬沙坦对缺血性心肌病血尿酸(UA)和心功能的影响。方法 78例缺血性心肌病患者随机分为A组和B组,每组39例。A组采用福辛普利片进行治疗,B组给予缬沙坦胶囊治疗。比较两组患者UA与心功能改善情况。结果治疗结果显示,A、B组患者治疗后的心功能改善情况均优于治疗前(P<0.05),A组与B组心功能改善效果组间比较差异无统计学意义(P>0.05);B组患者治疗前后的UA含量比较差异具有统计学意义(P<0.05);A组患者治疗前后的UA含量比较差异无统计学意义(P>0.05)。结论在治疗缺血性心肌病时,福辛普利与缬沙坦对改善患者心功能情况并无差异,而缬沙坦可以有效降低患者UA水平。

ObjectiveTo research influence by fosinopril and valsartan on uric acid （UA） and cardiac function in ischemic cardiomyopathy.MethodsA total of 78 patients with ischemic cardiomyopathy were randomly divided into group A and group B, with 39 cases in each group. The group A received fosinopril tablets for treatment, and the group B received valsartan capsules for treatment. Improvements of UA and cardiac function were compared between the two groups.ResultsBoth groups had better improvement of cardiac function after treatment than those before treatment （P〈0.05）. There was no statistically significant difference of cardiac function between groups A and B （P〉0.05）. The difference of UA contents in group B had statistical significance before and after treatment （P〈0.05）, while the difference of UA in group A had no statistical significance （P〉0.05）. ConclusionIn treating ischemic cardiomyopathy, fosinopril and valsartan show no difference in improvement of cardiac function, while UA level can be remarkably reduced by valsartan.